Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab N01 Plus Sintilimab and Lenvatinib in TFE3-Rearranged Renal Cell Carcinoma
NCT07715565Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, sintilimab, lenvatinib in renal cell carcinoma (RCC), sponsored by West China Hospital of Sichuan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ipilimumabsintilimablenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07715565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715565.